Business Acquisition (Details Narrative) $ in Thousands |
Oct. 23, 2020
USD ($)
ft²
|
Mar. 31, 2021
USD ($)
|
Dec. 31, 2020
USD ($)
|
|---|---|---|---|
| Estimated consideration, total | $ 2,500 | ||
| Good will | 901 | $ 901 | $ 901 |
| Indefinite-lived intangible asset | 1,599 | ||
| Consulting Agreement [Member] | Mr. Gurnani [Member] | |||
| Aggregate cost consideration | 300 | ||
| CLIA License [Member] | |||
| Indefinite-lived intangible asset | 1,300 | ||
| Plaza Medical Laboratory Corp [Member] | |||
| Cash consideration on acquisition | $ 2,500 | ||
| Laboratory square foot | ft² | 4,000 |
| X | ||||||||||
- Definition Aggregate cost consideration. No definition available.
|
| X | ||||||||||
- Definition Area of land held. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of assets acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|